|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.2900 - 0.3290|
|52 Week Range||0.2260 - 0.7320|
|Beta (5Y Monthly)||2.39|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for ...
Cannabis Countdown: Top 10 Marijuana Industry News Stories of the Week Welcome to the Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana industry news stories ...
Liberty now displays its product availability and pricing in real-time on an easy-to-use online ordering platform empowering patients to shop for their favorite brands from their favorite local Liberty dispensary. Currently the service allows patients to reserve their products for pick-up only.
Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis announced today it will open its 23rd Florida dispensary in Lakeland, making it Liberty's second store to open in Polk County. The Lakeland location will open on Friday, January 17, 2020, subject to approval from the Florida Department of Health, and serve a population in excess of 110,000.
Zeifmans replaced MNP LLP (the "Former Auditor") as the Company's independent auditor to provide audit services for the Company effective December 18, 2019 . The appointment of Zeifmans has been approved by the directors of Liberty. There were no disagreements or unresolved issues with the Former Auditor on any matter of audit scope or procedures, accounting principles or policies, or financial statement disclosure.
"We continue to be laser focused on expanding our footprint throughout the state and this magnificent location in the heart of Orlando will help us attract a large population of patients in the central region of Florida ," said Victor Mancebo , Interim Chief Executive Officer of Liberty.
Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced today that it plans to open its 21st dispensary in Sarasota, Florida, subject to approval from the Florida Department of Health.
Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced today that it has been cleared by the Florida Department of Health to open the doors to its record 20th Florida location in the central Gulf Coast city of Bradenton in Manatee County.
G Pen products will be available with Liberty's unique Werc Shop terpene blend. Grenco Science, the maker of the G Pen Gio, Pro, Connect, Elite and Nova, is a leader in engineering advanced cannabis vaporizers, known for its aesthetics, portability, functionality, and user experience. Grenco Science launched the G Pen in 2012 and was one of the first vaporizer companies to develop a portable device for cannabis concentrates.
Even after a sector bounce the last couple of days, the Canadian cannabis sector is down substantially for the year. The Canadian cannabis sales haven’t lived up to expectations after recreational cannabis legalization in October 2018 and the provinces over ordered product during the prior quarter. The vast majority of the sector faced returns and allowances that crushed the sector stocks during the recent Q3 reporting season.The major problem hurting the sector is over supply in dried flower due to a general focus of the big Canadian firms on the farming aspects of cultivation. The companies likely to succeed in 2020 are the ones in ancillary markets that benefit from sales growth in Canada and not impacted by the pricing pressure under cutting actual growth in kilograms sold in the country. Even better are companies with the financial resources to invest in the sector at the lows while most cannabis companies are reeling back investments and closing facilities due to financing issues.Despite a global market still foretasted to top $200 billion in annual sales in the distant future, investors need to dig deep to find cannabis stocks bucking the trend under the radar of the general investor. A lot of these stocks are playing into the Cannabis 2.0 rollout in 2020 along with benefiting from the eventual retail store roll-out next year.We’ve delved into three cannabis companies that hit the mark during the last quarter and offer investors a chance to outperform the market.Stock Comparison Tool | TipRanksMediPharm Labs (MEDIF)The Canadian cannabis extraction company grew revenues substantially in Q3 providing the support for the stable stock price here. Unlike the other Canadian cannabis companies, the company generates solid adjusted EBITDA profits due to solid margins by participating in the actual growth in demand in the industry without the oversupply issues.For Q3, revenues increased 38% sequentially to C$43.4 million. The key to the stock is that MediPharm isn’t just growing for the sake of growing. The company generated an adjusted EBITDA margin of 23% in Q3 driving C$10.1 million in EBITDA profits. For the YTD period, the adjusted EBITDA profit is C$22.1 million placing the cannabis extraction firm in a strong position as they operate in a sector offering a premium service without the high level of competition in the sector highly focused on cultivation.MediPharm is on a major capacity expansion plan with a recent increase in annual cannabis extraction processing capacity to 300,000 kg. The importance here is expanding capacity along with demand versus outlandish goals before the market was ready.Due to the stock only trading with a market cap of $400 million as MediPharm has slipped from the highs due to general sector weakness, the stock is a solid bargain. The company is already generating annualized revenue growth of ~C$170 million while expecting substantial growth in 2020Based on all the above factors, Wall Street analysts are thoroughly impressed with MediPharm. TipRanks' survey of stock analyst ratings shows that, on average, Wall Street considers the cannabis stock a "strong buy," and capable of delivering as much as a 105% profit if it reaches its $104 price target. (See MediPharm's price targets and analyst ratings on TipRanks)Valens GroWorks (VGWCF)Similar to MediPharm, Valens GroWorks works in the cannabis extraction sector. The company reported FQ3 results back in October that were highly impressive so their inclusion on the list was based on a recent investment in cannabis-infused beverages.The company bought all of the outstanding shares of Southern Cliff Brands d/b/a Pommies cider in a cash and stock deal valued at C$7.5 million. The deal allows Valens to enter the high-growth edibles and beverages market in Canada with an estimated value of C$2.0+ billion according to Deloitte.Valens plans to invest C$10.0 million in the facility to create a facility with beverage capacity of 40 million units allowing the company to progress with white label product offerings. The recent agreement with the cannabis division of Iconic Brewing fits perfectly into this facility.The stock has a $300 million market cap and analyst estimates for FY20 revenues of $128 million. The purchase of Pommies and the recent $50 million deal with BRNT for 2.2 million vape pens over two years should help Valens easily surpass these analyst estimates.Valens has slipped under most analysts’ radar; the stock’s Moderate Buy consensus is based on just two recent ratings. With shares trading at $2.55, the $6.78 average price target suggests room for a 176% upside. (See Valens' price targets and analyst ratings on TipRanks)Liberty Health Sciences (LHSIF)Liberty Health Sciences is the wild card of the group. The company recently reported quarterly results where revenues soared 379% to C$10.6 million. Sales were up sequentially from C$5.5 million in the prior quarter.The Toronto based company actually focuses on running dispensaries in Florida selling medical cannabis. For the month of August 2019, Liberty Health hit monthly sales of C$4.6 million for a quarterly run rate already reaching over C$13.8 million and the state still has the catalyst of approving recreational cannabis at a future date.The company now operates 19 dispensaries across Florida with only 16 dispensaries open at the end of the last quarter. Liberty Health plans to open another 17 retail stores with 10 having lease agreements already in place and another seven under negotiation.The stock only has a market value of $125 million with an annual revenue run rate already topping C$55 million and plans to more than double the dispensaries open at the end of the last quarter in a limited amount of time. The position in Florida makes Liberty Health an acquisition target for a U.S multi-state operator looking to expand into one of the biggest medical cannabis markets with the potential upside of recreational cannabis approval in the future.To find good ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Profits for most cannabis companies aren't expected in the near future, so when companies to announce positive EBITDA in their earnings report, it's important to look under the hood more to find out what the nature of those results entail, and if they are sustainable.In this article we'll look at OrganiGram Holdings, Aphria, and Liberty Health Sciences, all of which have been posting positive EBITDA.TipRanks' Stock Comparison toolOrganiGram (OGI)OrganiGram has received some accolades because of it being able to generate positive earnings for four quarters in a row. The good news is because of its smaller size in comparison to a number of market leaders, it should be able to continue to boost revenue and earnings for now, as it operates out of one 490,000 square foot facility, which is expected to increase the amount of kilograms it grows annually from 36,000 to 113,000 by the end of 2019.OrganiGram is also one of three companies based in Canada that have sales agreements in all the 10 provinces in Canada.One of the major strengths of Organigram is its unique growing system that allows it to grow almost twice as much cannabis per square foot than its closest competitors, and in most cases, it's over twice as much per square foot.Another competitive advantage for now is its being the only large cannabis producer in Canada located in the province of New Brunswick. While it isn't a highly populated region, it does have the most cannabis usage based upon percentage of population. It also has little competition at this time.I think Organigram should be able to remain the dominant player in the Eastern province for some time, but once the larger players saturate other areas of Canada, once more retail outlets are operational, there's not doubt to one degree or another, they'll start to focus on New Brunswick. That will take time, so Organigram should enjoy a competitive advantage in the near term.Because of its one facility, increase in production capacity, and not having to spend on expansion, it should continue to improve earnings in the quarters ahead.On the negative side, that which is a strength for Organigram under the current market conditions, will eventually become a weakness as the number of retail outlets in Canada scale across the nation. Its much larger competitors will be able to lower costs per gram as they scale in conjunction with the increase of retail stores.The other concern is what Organigram will do for growth once it reaches production capacity. By that time its competitors should be starting to generate positive EBITDA as well, and it will struggle to show how it can match the long-term growth trajectory of many of its peers. Consequently, its share price will come under pressure.On the other hand, Organigram also faces the same limitations its competitors do because of lack of places to sell cannabis in Canada. Because of its location and size, it is probably not going to be affected as much, but its revenue numbers have been subdued because of the ongoing shortage of retail outlets.For now, there are questions concerning revenue growth that have no apparent answers because of its relatively small amount of production capacity when its fully operational.With a stock price down 70% since its May IPO, you might think that OGI is running out of juice -- but Wall Street begs to differ. TipRanks' survey of stock analyst ratings shows that, on average, Wall Street considers the dried cannabis specialist a "strong buy," and capable of delivering as much as 246% profit if it reaches its $8.00 price target. (See OrganiGram stock analysis on TipRanks)Aphria (APHA)Not that long ago the market was very positive on the assumed potential of Aphria. Most of that came from the company posting a profit in a couple of quarters in a row. But once the dust settled and investors took a closer look, the outcome wasn't as impressive as it initially seemed, based upon headlines in the media.When looking closer at the numbers it was found that the profits weren't coming from operations, but from other sources, including CC Pharma, a German distributor.One major positive catalyst Aphria has going for it is it's doubling its production capacity, which should, over time, allow it to improve operational results from scale and increased revenue.On the down side, Aphria lost its long-term supply deal with Aleafia, which it inherited with the acquisition of Emblem. This came from Aphria's inability to come close to meeting the 25,000 kilograms it was contracted for, selling only 2,226 kilograms over a period of four months ending on August 31.On the face of it, it would appear this could be a positive because of low margins associated with wholesale pot, but in reality, it's profitable because it costs much less to convert, package and deliver.In the short term Aphria is going to struggle to replace the revenue it was expected to generate from Aleafia.After removing the gains outside of operations, net income plummeted from a $16 million gain to a loss of $30 million.Even though Aphria reiterated it full year 2020 guidance of $650 t0 $700 million in revenue and $88 to $95 million in adjusted EBITDA, I think it's far too aggressive to reach.Some of this will determined by, as with Organigram, how rapidly retail cannabis stores are rolled out, and the impact of cannabis derivatives on its performance.TipRanks reveals the cannabis player as one drawing bullish attention on Wall Street. Out of 7 analysts polled in the last 3 months, 7 rate a Buy on Aphria stock, while only one suggests Sell. Based on these ratings, the average $8.47 price target on X stock translates into upside of almost 100% from the current share price. (See Aphria stock analysis on TipRanks)Liberty Health Sciences (LHSIF) Recent numbers from Liberty Health Sciences show that while it had some help from non-operating events such as the sale of Chestnut Hill Tree Farm and a boost from fair value adjustments to its biological assets, it still would have at least broke even.The sale of Chestnut Hill Tree Farm provided $14 million to the bottom line of the company.In the latest quarter it posted a profit of $22.9 million with the inclusion of non-operational items. Operating profit came in at over $9.2 million.A key reason for the solid performance was the ability of the company to have its operating expenses climb by a modest 3 percent year-over-year, while it was able to have sales jump by almost 380 percent.One of the strengths of Liberty Health is it is able to produce solid results by focusing solely on the Florida market. This lowers costs because the firm doesn't need to increase spending in order to expand to other markets.Canadian companies on the other hand have to spend more to expand in markets around the world in order to generate sustainable, long-term growth.This is why in the near term companies competing in the U.S., in general, have superior results than Canadian companies, although that doesn't apply to the MSOs that are looking to take a permanent long-term lead in the U.S. market by issuing shares and taking on more debt for the purpose of acquiring assets.ConclusionOrganiGram, Aphria, and Liberty Health Sciences. have enjoyed some positive press and response to their ability to generate a profit before other cannabis companies have been able to.In the case of Aphria, it has yet to prove it can consistently produce a profit when not including non-operational items. It will benefit from increased production capacity, but as with Organigram, has to wait until it can fully take advantage of the potential demand in the Canadian market with the increase in retail outlets. It also will have to prove it can boost revenue and wident margins from derivative sales over the next couple of quarters starting in 2020.Of these three companies Liberty Health Sciences and Organigram should be able to continue to increase their revenue and earnings for some time. That said, as the companies stand today, eventually they'll face a ceiling on revenue and earnings that they'll have to deal with. For now, both are able to keep costs low because of their primary focus on a more limited geographic region. What happens when those markets are saturated will determine the long-term sustainability of their growth potential.That time isn't likely to be here for a couple of years, but when the limitations of their business models are met, they will be forced to expand beyond their current capabilities, which will increase costs and put pressure on margins and earnings.For now, I see OrganiGram Holdings and Liberty Health Sciences having more potential to sustainably generate profits, while Aphria will without a doubt outperform them on revenue. How the market responds to those results will determine the share price of the companies.At this time the market is rewarding those that are able to reduce costs and generate a profit, but when market sentiment for cannabis improves, Aphria could be considered a much better long-term holding with more potential to reward shareholders.To find other good ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
On the other hand, we saw a series of bad news coming out of major cannabis companies. MedMen Enterprises Inc. (CSE: MMEN) (OTC: MMNFF) tumbled on a substantial growth in its net losses, which came in at $82.9 million for the fourth quarter, more than double the loss reported in the same period last year.
Liberty Health Sciences Inc. (CSE:LHS) (OTC: LHSIF ) reported Thursday consolidated second-quarter net sales of CA$10.63 million ($8.1 million) versus CA$2.22 million one year ago. The company posted ...
TORONTO, Oct. 31, 2019 /PRNewswire/ - Liberty Health Sciences Inc. (LHS.CN) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced its financial results for the second quarter ended August 31, 2019. The significant year-over-year increase in revenue was driven by the Company's opening of new dispensaries and delivery locations, as well as experiencing an upsurge in same store sales volume and an uptick in the registered patient base for Medical Marijuana Use in Florida. The Company recorded net income for the quarter ended August 31, 2019 of $22,884,261, compared with a net loss of $5,605,355 for the quarter ended August 31, 2018.